Dissolution was assessed for intact and crushed dosage forms. In vitro dissolution techniques were used to compare the opioid release from a variety of ER opioid formulations. The goal of this study was to assess the ability of oxycodone DETERx (Xtampza ® ER, Collegium Pharmaceutical, Inc., Canton, MA, USA) and other commercially available ER opioid formulations with and without physicochemical abuse-deterrent characteristics to be manipulated by crushing in an in vitro setting. Patients may also manipulate ER tablets to facilitate swallowing, without recognizing that manipulation could increase release rate. Recreational opioid users often manipulate ER formulations to achieve a high plasma concentration in a short amount of time, resulting in a more rapid and intense high. Extended-release (ER) opioids are associated with high rates of abuse.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |